An Exploratory Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Design Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of AZD1722 in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria

Trial Profile

An Exploratory Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Design Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of AZD1722 in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Sep 2015

At a glance

  • Drugs Tenapanor (Primary)
  • Indications Proteinuria; Renal failure
  • Focus Therapeutic Use
  • Sponsors Ardelyx
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 30 Jul 2015 According to an AstraZeneca media release, development of tenapanor in chronic kidney disease patients with type-2 diabetes mellitus has been discontinued for safety and efficacy reasons.
    • 05 May 2015 Results published in Ardelyx media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top